News Category
American Fusion has advanced its Texatron fusion program into active testing with record pressures, potentially accelerating the path to commercial fu...
The conference aims to connect investors with under-covered growth and life sciences firms, highlighting the importance of direct engagement in today’...
SuzieQ Holdings Inc. will be featured at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, underscoring its role in devel...
A new study confirms that treating certain emergency room patients while seated, rather than waiting for a bed, significantly reduces wait times, pote...
Helus Pharma reports progress in its Phase 3 program for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and advances its ...
Helus Pharma's appointment of Michael Halstead as CEO signals strategic leadership to advance its Phase 3 depression program and potential commerciali...
Ocumetics Technology Corp. has completed the second tranche of its private placement, securing $2.5 million to advance its first-in-human clinical tri...
VERAXA Biotech AG shareholders approved key governance changes and financing flexibility with over 99.94% support, enabling the company to pursue grow...
VERAXA Biotech AG (NASDAQ: VRXA) has advanced its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, leveraging...
Gerresheimer has started operations at a new plant in Zhenjiang Dagang, China, doubling its production capacity for primary packaging for injectable p...
Darwin AG has changed its name to Novogenia AG to align its corporate identity with its core operating brand, strengthening its international presence...
NanoViricides progresses NV-387, a broad-spectrum oral antiviral, toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, where no ...
Redwood AI Corp. has been included in the CSE25 Index, reflecting its growth and potential to attract institutional and retail investors interested in...
Helus Pharma announced fiscal 2026 financial results and clinical pipeline updates, emphasizing the Phase 3 APPROACH trial for HLP003 in major depress...
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting its novel drug candidate Lucid-MS, which directly targets myelin repair in m...
Advancements in nanomedicine and drug-delivery systems, such as Oncotelic Therapeutics' Deciparticle platform, are poised to enhance the efficacy of e...
Quantum BioPharma Ltd. is advancing its novel MS therapy, Lucid-MS, toward Phase 2 trials, which directly protects myelin rather than modulating the i...
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-restricted activation and reduced toxicity...
Redwood AI Corp. is highlighted as a company to watch for its AI-powered platforms that aim to accelerate chemistry research and development in pharma...
NanoViricides announced approval from the DRC's Pillar Committee to proceed with a Phase II trial for NV-387 Oral Gummies against the Bundibugyo ebola...
Helus Pharma announces its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright conference, highlighting the company's pro...
Onco-Innovations Limited announced the initiation of process development and scale-up for its drug candidate ONC010, a key step toward IND-enabling st...
Quantum BioPharma reported favorable safety data from Phase 1 trials of LUCID-MS, a novel therapy aimed at protecting myelin and addressing neurodegen...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference, providing commercialization updates and milestones for it...
GeoVax CEO David Dodd comments on recent pharmaceutical acquisitions that signal a strategic shift toward prioritizing vaccine innovation, health secu...
Quantum BioPharma's co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial success of unbuzzd, with an upcoming Phas...
Helus Pharma announces its participation in the Jefferies Global Healthcare Conference, highlighting its clinical-stage development of novel serotoner...
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 may be evaluated for the Bundibugyo Ebola outbreak, citing its host-targete...
SureNano Science Ltd. is advancing GEP-44, a patented GLP-1 peptide targeting obesity and metabolic disorders, aiming to compete with blockbuster drug...
Oncotelic Therapeutics has integrated 28 million scientific abstracts into its PDAOAI platform, positioning itself as a key player in the AI-driven dr...
Telomir Pharmaceuticals announced publication of peer-reviewed preclinical data showing Telomir-Zn improves survival and reduces oxidative stress and ...
Lantern Pharma announced FDA clearance for protocol amendments to its Phase 2 HARMONIC trial, focusing LP-300 on EGFR-mutant never-smokers with advanc...
NanoViricides emphasizes the potential of its oral drug candidate NV-387 for treating Ebola and other filoviruses, positioning it as a key pandemic pr...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Holdings announced first-quarter 2026 progress including expansion of its ovarian cancer trial for lead candidate LB-100 and conti...
Dogwood Therapeutics announced first quarter 2026 financial results with pipeline progress including Phase 2b data for Halneuron expected in fall 2026...
Innovations in crossing the blood-brain barrier, such as Oncotelic's intranasal nose-to-brain delivery system, are poised to transform CNS treatment a...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
The outbreak of hantavirus on the MV Hondius cruise ship, resulting in three fatalities, underscores the dangers of this rare infection and the import...
NanoViricides' NV-387, a broad-spectrum antiviral, has been granted Orphan Drug Designation by the FDA for measles, offering incentives and supporting...
VolitionRx announces a technical milestone in detecting nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototyp...
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 PARADIGM trial of HLP003, a Breakthrough Therapy-designated trea...
Ventripoint Diagnostics Ltd. announces that its strategic partner Lishman Global Inc. has submitted the VMS+ 4.0 system for NMPA approval in China, wi...
Formycon AG will publish its fiscal year 2025 results on April 22, 2026, host a conference call, and participate in several international investor con...
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over 20 years of neuroscience medical a...
GeoVax Labs announced its 2025 financial results and business update, highlighting plans to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine i...
Kairos Pharma's recognition with the 2026 Pinnacle Award highlights its pioneering work in targeting cancer drug resistance through its lead candidate...
